The expression miRNA-195 in a sample of Iraqi breast cancer patients.

Breast carcinoma is the most prevalent cancer-related cause of death in women, and metastasis is the main factor in morbidity. The total number of new cases of cancer in Iraq during the year 2019 was 35,864. New non-invasive prognostic biomarkers are needed for the rapid recognition and differentiation between breast cancer (BC) stages for treatment choice improvement. MicroRNA (miRNA) are small, noncoding RNAs regulating gene expression and involve many cellular processes, including metastasis. Circulating miRNAs (detected in the blood) show considerable potential as biomarkers for helping diagnosis or tracking treatment efficacy. Materials and Methods: total RNA was extracted from serum from (n=50) patients and (n=26) healthy control to measure the MicroRNA 195 expression using SYBR green-based real-time RT-PCR technology. As a result, the expression levels miR-195 in breast cancer patients’ serum were significantly increased (up-regulated) compared to those in the normal adjacent serum. BC group showed a higher significant miR-195 expression (upregulation) when compared with those in the control group. While the highest expression of miR195 was recorded in stage II. Keywords: Breast Cancer, MicroRNA, miR-195, Stage, Iraq